Suicidality and montelukast

Expert Opinion on Drug Safety

Volumn 8, Issue 3, 2009, Pages 273-282

  Manalai, Partam ^a,b   Woo, Jong Min ^a,c,d   Postolache, Teodor T ^a,b,e  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b St Elizabeths Hospital   (United States)

^c Inje University College of Medicine   (South Korea)

^d Inje University   (South Korea)

^e National Center for the Treatment of Phobias   (United States)

Author keywords

Allergic rhinitis; Allergy; Anxiety; Asthma; Leukotriene antagonists; Montelukast (Singulair ); Mood disorders; Self harm; Suicidal attempt; Suicidal behavior; Suicidal ideation; Suicidality; Suicide; Suicide risk factors

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PRANLUKAST; ZAFIRLUKAST; ZILEUTON;

AGGRESSION; ALLERGY; ANXIETY DISORDER; ASTHMA; BEHAVIOR CHANGE; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; DEPRESSION; DREAM; DROWSINESS; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; INSOMNIA; IRRITABILITY; LASSITUDE; MALAISE; MOOD CHANGE; NIGHTMARE; PATIENT COMPLIANCE; RESTLESSNESS; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT;

ACETATES; HUMANS; HYPERSENSITIVITY; QUINOLINES; RISK FACTORS; SUICIDE;

EID: 67649337296     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330902932688     Document Type: Review

References (90)

1. National Center for Injury Prevention and Control. WISQARS Leading Causes of Death Reports, 1999 - 2005. [CDC Statistics] 2008; Available from: http://webappa.cdc.gov/sasweb/ncipc/leadcaus10.html [Cited 23/1/2008]
2. List of SUPRE publications. 2008; Available from: http://www.who.int/ mental-health/resources/suicide/en/index.html [Cited 28/1/2009]
3. Bertolote JM, Fleischmann A, De Leo D, et al. Suicide attempts, plans, and ideation in culturally diverse sites: the WHO SUPRE-MISS community survey. Psychological Medicine 2005;35(10):1457-1465 (Pubitemid 41430683)
4. Nock MK, Guilherme B, Bromet EJ, et al. Cross-national Prevalence and Risk Factors For Suicidal Ideatoin, Plans, and Attempts. The British Jounral of Psychiatry 2008;192:98-105
5. Patterson WM, Dohn HH, Bird J, Patterson GA. Evaluation of suicidal patients: The SAD PERSONS scale. Psychosomatic 1989;24(4):343-5, 8-9
6. Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of Suicidal Events in the FDA's Pediatric Suicidal Risk Analysis of Antidepressants. Am J Psychiatry 2007;164:1035-1043 (Pubitemid 47121392)
7. Brown G. Suicide Assessment in Clinical Trial Research. International Suicidality Capstone Meeting: Academia, Government, and Industry Forum; 2009; New York State Psychiatric Institute; 2009
8. Assessment and Treatment of Patients With Suicidal Behaviors. 2003; Available from: http://www.psychiatryonline.com/pracGuide/pracGuideTopic-14.aspx [Cited 24/11/2008]
9. Brent DA, Melhem N. Familial Transmission of Suicidal Behavior. Psychiatr Clin North Am 2008;31(2):157-177 (Pubitemid 351551427)
10. Chaudron LH, Caine ED. Suicide among women: A critical Review. J Am Med Womens Assoc 2004;59(2):125-134
11. Mann J. Neurobiology of suicidal behaviour. Nat Rev Neurosci 2003;4(10):819-828 (Pubitemid 37314404)
12. Kessler RC, Berglund P, Borges G, et al. Trends in Suicide Ideation, Plans, Gestures, and Attempts in the United States, 1990-1992 to 2001-2003. JAMA 2005;293(20):2487-2495
13. Laughren T. Suicidality and Psychiatric Drug Development: an FDA Perspective. International Suicidality Capstone Meeting: Academia, Government, and Industry Forum; 2009; New York State Psychiatric Institute; 2009
14. Gibbons R, Brown CH, Hur K, et al. Early Evidence on the Effects of Regulators' Suicidality Warnings on SSRI Prescriptions and Suicide in Children and Adolescents. Am J Psychiatry 2007;164:1356-1363 (Pubitemid 47461135)
15. Gibbons RD, Brown CH, Hur K, et al. Relationship Between Antidepressants and Suicide Attempts: An Analysis of the Veterans Health Administration Data Sets. Am J Psychiatry 2007;164:1044-1049 (Pubitemid 47121393)
16. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 2006;163:1898-1904 (Pubitemid 44807781)
17. Gibbons RD, Segawa E, Karabatsos G, et al. Mixed-effects Poisson regression analysis of adverse event reports: the relationship between antidepressants and suicide. Stat Med 2008;27(11):1814-1833 (Pubitemid 351618880)
18. Vitiello B, Swedo S. Antidepressant medications in children. NEJM 2004;350(15):1489-1491 (Pubitemid 38477772)
19. Teicher M, Glod C, Cole J. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990;147:207-210 (Pubitemid 20060476)
20. Suicidality in Children and Adolescents Being Treated With Antidepressant Medications. 2004; Available from: http://www.fda.gov/cder/drug/ antidepressants/SSRIPHA200410.htm [Cited 24/112008]
21. FDA Requires Warnings about Risk of Suicidal Thoughts and Behavior for Antiepileptic Medications. 2008; Available from: http://www.fda.gov/bbs/topics/ NEWS/2008/NEW01927.html [Cited 24/112008]
22. FDA Issues Public Health Advisory on Chantix. 2008; Available from: http://www.fda.gov/bbs/topics/NEWS/2008/NEW01788.html [Cited 22/12/2008]
23. Isotretinoin (marketed as Accutane) Capsule Information. 2007; Available from: http://www.fda.gov/cder/drug/infopage/accutane/default.htm#warning [Cited 24/11/2008]
24. Early Communication About an Ongoing Safety Review of Montelukast (Singulair). 2008; Available from: http://www.fda.gov/cder/drug/early-comm/ montelukast.htm [Cited 24/11/2008]
25. Update of Safety Review: Follow-up to the March 27, 2008, Communication about the Ongoing Safety Review of Montelukast (Singulair). 2009; Available from: http://www.fda.gov/cder/drug/early-comm/montelukast-200901.htm [Cited 18 2009]
26. Goodwin RD, Castro M, Kovacs M. Major Depression and Allergy: Does Neuroticism Explain the Relationship? Psychosomatic Medicine 2006;68:94-98
27. Timonen M, Jokelainen J, Hakko H, et al. Atopy and depression: results from the Northern Finland 1966 Birth Cohort Study. Mol Psychiatry 2003; 8(8):738-744
28. Timonen M, Jokelainen J, Silvennoinen-Kassinen S, et al. Association between skin test diagnosed atopy and professionally diagnosed depression: a Northern Finland 1966 Birth Cohort study. Biol Psychiatry 2002;52(4):349-355
29. Hurwitz EL, Morgenstern H. Cross-Sectional Associations of Asthma, Hay Fever, and Other Allergies with Major Depression and Low-Back Pain among Adults Aged 20-39 Years in the United States. Am J Epidemiol 1999;150(10 ):1107-1116 (Pubitemid 29531948)
30. Bell I, Jasnoski M, Kagan J, King D. Depression and allergies: survey of a nonclinical population. Psychother Psychosom 1991;55(1):24-31
31. Shaffer D. Suicide: risk factors and the public health. Am J Public Health 1993;83(2):171-172 (Pubitemid 23046470)
32. Robins E, Murphy GE, Wilkinson RHJ, et al. Some Clinical Considerations In The Prevention Of Suicide Based On A Study Of 134 Successful Suicides. Am J Public Health Nations Health 1959;49(7):888-899
33. Barraclough B, Bunch J, Nelson B, Sainsbury P. A hundred cases of suicide: clinical aspects. Br J Psychiatry 1974;(125):355-373
34. Timonen M, Viilo K, Hakko H, et al. Is seasonality of suicides stronger in victims with hospital-treated atopic disorders? Psychiatry Res 2004;30(126):2
35. Bender BHM. Neuropsychiatric effects of medications for allergic diseases. J Allergy Clin Immunol 1995;95(2):523-528
36. Postolache TT, Komarow H, Tonelli LH. Allergy: a risk factor for suicide? Current Treatment Options in Neurology 2008;10:363-376
37. Eder W, Ege MJ, von Mutius E. The asthma epidemic. NEJM 2006;355(21):2226-2235 (Pubitemid 44791164)
38. Kay AB. Allergy and allergic diseases- first of two parts. NEJM 2001;344(1):30-37
39. Holgate ST. The epidemic of allergy and asthma. Nature 1999;402(6760 Suppl):B2-4
40. Elias JA, Lee CG, Zheng T, et al. New insights into the pathogenesis of asthma. J Clin Invest 2003;111(3):291-297 (Pubitemid 36182201)
41. Busse WW, Lemanske RF. Asthma. NEJM 2001;344(5):350-362
42. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature 2008;454:445-454
43. Salvi SS, Krishna MT, Sampson AP, Holgate ST. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest 2001;119(5):1533-1546 (Pubitemid 32686041)
44. Hardman JG, Limbird LE, editors, Drugs used in the treatment of asthma. Goodman & Gilmann's the pharmacological basis of therapeutics. 10 edition. New York: McGraw-Hill 2001;733-750
45. Drazen D, Israel E, O'byrne P. Treatment of Asthma with Drugs Modifying the Leukotriene Pathway. NEJM 1999;340(3):197-206
46. Brink C, Dahlen S-E, Drazen J, et al. International Union of Pharamcology XXXVII. Nomenclature for leukotiene and lipoxin receptors. Pharmacol Rev 2003;55:195-227
47. Yokomizoa T, Katoa K, Terawakia K, et al. A second leukotriene B4 receptor, BLT2: a new therapeutic target in inflammation and immunological disorders. J Exp Med 2000;192(3):421-432
48. Kanaoka Y, Boyce J. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol 2004;173(3):1503-1510 (Pubitemid 38971578)
49. Woszczek G, Pawliczak R, Qi H-Y, et al. Functional characterization of human cysteinyl leukotriene 1 receptor gene structure. J Immunol 2005;175:5152-5159 (Pubitemid 41456399)
50. Bisgaard H, Groth S, Madsen F. Bronchial hyperreactivity to leucotriene D4 and histamine in exogenous asthma. Br Med J (Clin Res Ed) 1985;290(6480):1468-1471 (Pubitemid 15076481)
51. Welch SJ, Messias E, Clarke DE, Goodwin RD. Allergies and suicidality: results from the National Comorbidity Survey Replication (NCS-R). New research [abstract 2:030]. American Psychiatric Association 161st Annual Meeting; Washington DC; 2008
52. Ajdacic-Gross V, Bopp M, Sansossio R, et al. Diversity and Change in Suicide Seasonality over 125 Years. J Epidemiol Community Health 2005;59(11):967-972 (Pubitemid 41527423)
53. Chew K, McCleary R. The spring peak in suicides: a cross-national analysis. Soc Sci Med 1995;40(2):223-230
54. Flisher AJ, Parry CDH, Bradshaw D, Juritz JM. Seasonal variation of suicide in South Africa. Psychiatry Res 1997;66(1):13-22 (Pubitemid 27111376)
55. Cantor C, Hickey P, De Leo D. Seasonal variation in suicide in a predominantly Caucasian tropical/subtropical region of Australia. Psychopathology 2000;33(6):303-306 (Pubitemid 30825350)
56. Massing W, Angermeyer M. The monthly and weekly distribution of suicide. Soc Sci Med 1985;21(4):433-441 (Pubitemid 16137452)
57. Retamal PC, Humphreys D. Occurrence of suicide and seasonal variation. Rev Saúde Pública 1998;32(5)
58. Souêtre E, Wehr T, Douillet P, Darcourt G. Influence of environmental factors on suicidal behavior. Psychiatry Res 1990;32(3):253-263 (Pubitemid 20214381)
59. Maes M, De Meyer F, Thompson P, et al. Synchronized annual rhythms in violent suicide rate, ambient temperature and the light-dark span. Acta Psychiatrica Scandinavica 2007;90(5):391-396 (Pubitemid 24331614)
60. Barker A, Hawton K, Fagg J, Jennison C. Seasonal and weather factors in parasuicide. Br J Psychiatry 1994;165:375-380 (Pubitemid 24274157)
61. Salib E, Gray N. Weather conditions and fatal self-harm in North Cheshire 1989-1993. Br J Psychiatry 1997;171:473-477
62. Postolache TT, Mortensen PB, Tonelli LH, et al. A history of hospitalization for mood disorders is associated with a greater suicide rate ratio in spring. Personal Communication. 2009
63. Timonen M, Jokelainen J, Herva A, et al. Presence of atopy in first-degree relatives as a predictor of a female proband's depression: Results from the Northern Finland 1966 Birth Cohort. J Allergy Clin Immunol 2003;111(6):1249-1254
64. Postolache T, Stiller J, Herrell R, et al. Tree pollen peaks are associated with increased nonviolent suicide in women. Mol Psychiatry 2005;10:232-235 (Pubitemid 40432675)
65. Timonen M. THE ASSOCIATION BETWEEN ATOPIC DISORDERS AND DEPRESSION: The Northern Finland 1966 Birth Cohort Study. 2003 Available from: http://herkules.oulu.fi/isbn9514271556/isbn9514271556.pdf
66. Goodwin RD, Eaton WW. Asthma, Suicidal Ideation, and Suicide Attempts: Findings From the Baltimore Epidemiologic Catchment Area Follow-Up. Am J Public Health 2005;95(4):717-722
67. Kimata H. Prevalence of Suicidal Ideation in Patients with Atopic Dermatitis. Suicide Life Threat Behav 2006;36(1):120-124
68. Postolache TT, Roberts DW, Langenberg P, et al. Allergen Specific IgE, Number and Timing of Past Suicide Attempts, and Instability in Patients with Recurrent Mood Disorders. Int J Child Health Hum Dev 2008;1(3):297-304
69. Reiss T, Chervinsky P, Dockhorn R, et al. Montelukast, A Once-Daily Leukotriene Receptor Antagonist, In the Treatment of Chronic Asthma: A Multicenter, Randomized, Double-Blind Trial. Arch Intern Med 1998;158(11):1213-1220
70. Dean T, Gary K. Leukotriene Inhibitors in the Treatment of Allergy and Asthma. Am Fam Physician 2007;75:65-70 (Pubitemid 46064484)
71. Bisgaard H. Leukotriene Modifiers in Pediatric Asthma Management. Pediatrics 2001;107(2):381-390 (Pubitemid 32121256)
72. Biswas P, Wilton L, Pearce G, et al. Pharmacosurveillance and Safety of the Leukotriene Receptor Antagonist (LTRA), Montelukast. Clin Exp Allergy Rev 2001;1(3):300-304 (Pubitemid 33754905)
73. Netherlands Bijwerkingen Centrum Lareb. Montelukast and Depressive Symptoms. http://www.lareb.nl/documents/kwb-2006-4-montel.pdf;2007
74. Osborne S. Columbia University International Suicidality Capstone Meeting. International Suicidality Capstone Meeting: Academia, Government, and Industry Forum; 2009; New York State Psychiatric Institute; 2009
75. Posner K. Suicidality Issues in Clinical Trials: Columbia Suicidal Adverse Event Identification in FDA Safety Analyses. 2007; Available from: http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4306s1-01-CU-Posner.ppt [Cited 2/12/2008]
76. Katz R. Regulatory Perspective on Assessing Suicidality in Clinical Trials. International Suicidality Capstone Meeting: Academia, Government, and Industry Forum; 2009; New York State Psychiatric Institute; 2009
77. Sampson H, Portnoy JM. Joint statement on FDA investigation of Singulair from the ACAAI and AAAAI. Eur Ann Allergy Clin Immunol 2008;40(2):64
78. Holbrook JT, Harik-Khan R. Montelukast and Emotional Well-being as a Marker for Depression: Results from 3 Randomized, Double-maked Clinical Trials. J Allergy Clin Immunol 2008;122(4):8280829
79. Brunlöf G, Tukukino C, Wallerstedt S. Individual case safety reports in children in commonly used drug groups - signal detection. BMC Clin Pharmacol 2008;8(1):1-5
80. Posner K. The Value of Systematic Assessment: Initial Findings from Prospective Studies. International Suicidality Capstone Meeting: Academia, Government, and Industry Forum; 2009; New York State Psychiatric Institute; 2009
81. Klein DF. The Flawed Basis for FDA Post-Marketing Safety Decisions: The Example of Anti-Depressants and Children. Neuropsychopharmacology 2006;31(4):689-699
82. Libby AM, Brent DA, Morrato EH, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 2007;164:884-891 (Pubitemid 46972903)
83. Bridge JA, Greenhouse JB, Weldon H. Suicide Trends Among Youths Aged 10 to 19 Years in the United States, 1996-2005. JAMA 2008;300(9):1025-1026
84. Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ 2009;180(3):291-297
85. Brent DA. Antidepressants and pediatric depression - the risk of doing nothing. NEJM 2004;351(16):1598-1601 (Pubitemid 39350418)
86. Avorn J. Drug warnings that can cause fits - communicating risks in a data-poor environment. NEJM 2008;359(10):991-994
87. Kraemer G, Clarke A. The behavioral neurobiology of self-injurious behavior in rhesus monkeys. Prog Neuropsychopharmacol Biol Psychiatry 1990;14(Suppl):S141-68
88. Tonelli LH, Hoshino A, Katz M, et al. Acute stress promotes aggressive-like behavior in rats made allergic to tree pollen. Int J Child Health Hum Dev 1(3):305-310
89. Tonelli LH, Virk G, Joppy B, et al. Experimentally induced allergy to tree pollen induces depressive-like behavior and mast cell activation in the brain of female rats. Society of Biological Psychiatry Annual Meeting, Toronto, Canada; 2006
90. Tonelli L, Katz M, Kovacsics C, et al. Allergic rhinitis induces anxiety-like behavior and altered social interaction in rodents. Brain Behav Immun 2009 [Epub ahead of print]